TrialBioMed research international2014
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
V Vaccaro et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it